Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2 positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment

被引：1
|
作者：
Sim, S. H.
Park, I. H.
Jung, K. H.
Kim, S-B
Ahn, J-H
Lee, K-H
Im, S-A
Im, Y-H
Park, Y. H.
Sohn, J. H.
Kim, Y. J.
Lee, S.
Kim, H-J
Chae, Y. S.
Park, K-H
Nam, B-H
Lee, K. S.
Ro, J.
机构：
[1] Natl Canc Ctr, Goyang, South Korea
[2] Seoul Natl Univ Hosp, Seoul, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Korea Univ, Seoul, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea
[8] Seoul Natl Univ, Bundang Hosp, Bundang, South Korea
[9] Chung Ang Univ, Coll Med, Seoul, South Korea
[10] Dong A Univ, Coll Med, Busan, South Korea
[11] Kyungpook Natl Univ, Coll Med, Daegu, South Korea
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P6-17-23
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-17-23
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    N. U. Lin
    D. S. Seah
    R. Gelman
    S. Desantis
    E. L. Mayer
    S. Isakoff
    P. DiPiro
    I. E. Krop
    S. E. Come
    D. Weckstein
    E. P. Winer
    H. J. Burstein
    Breast Cancer Research and Treatment, 2013, 139 : 403 - 410
  • [32] SAFETY AND TOLERABILITY OF LAPATINIB IN COMBINATION WITH VINORELBINE (N) AND CAPECITABINE (C) AS SECOND LINE TREATMENT IN PATIENTS WITH HER2 POSITIVE METASTATIC BREAST CANCER (MBC)
    Bisagni, G.
    Bologna, A.
    Moretti, G.
    Gnoni, R.
    Boni, C.
    ANNALS OF ONCOLOGY, 2010, 21 : 113 - 113
  • [33] A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer
    Lin, N. U.
    Seah, D. S.
    Gelman, R.
    Desantis, S.
    Mayer, E. L.
    Isakoff, S.
    DiPiro, P.
    Krop, I. E.
    Come, S. E.
    Weckstein, D.
    Winer, E. P.
    Burstein, H. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (02) : 403 - 410
  • [34] Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer
    Saip, P.
    Eralp, Y.
    Ozkan, M.
    Karaca, H.
    Benekli, M.
    Cetin, B.
    Isikdogan, A.
    Kucukoner, M.
    Basaran, G.
    Sen, F.
    Un, O.
    Onur, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Lapatinib plus trastuzumab for HER-2 positive metastatic breast cancer: experience of use
    Garcia Munoz, C.
    Cortijo Cascajares, S.
    Canamares Orbis, I.
    Goyache Goni, M. D. P.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 892 - 893
  • [36] Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
    Burstein, Harold J.
    Keshaviah, Aparna
    Baron, Ari D.
    Hart, Ronald D.
    Lambert-Falls, Rosemary
    Marcom, P. Kelly
    Gelman, Rebecca
    Winer, Eric P.
    CANCER, 2007, 110 (05) : 965 - 972
  • [37] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    Gavila, J.
    De La Haba, J.
    Bermejo, B.
    Rodriguez-Lescure, A.
    Anton, A.
    Ciruelos, E.
    Brunet, J.
    Munoz-Couselo, E.
    Santisteban, M.
    Rodriguez Sanchez, C. A.
    Santaballa, A.
    Sanchez Rovira, P.
    Garcia Saenz, J. a.
    Ruiz-Borrego, M.
    Guerrero-Zotano, A. L.
    Huerta, M.
    Cotes-Sanchis, A.
    Lao Romera, J.
    Aguirre, E.
    Cortes, J.
    Llombart-Cussac, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 420 - 428
  • [38] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    J. Gavilá
    J. De La Haba
    B. Bermejo
    Á. Rodríguez-Lescure
    A. Antón
    E. Ciruelos
    J. Brunet
    E. Muñoz-Couselo
    M. Santisteban
    C. A. Rodríguez Sánchez
    A. Santaballa
    P. Sánchez Rovira
    J. Á. García Sáenz
    M. Ruiz-Borrego
    A. L. Guerrero-Zotano
    M. Huerta
    A. Cotes-Sanchís
    J. Lao Romera
    E. Aguirre
    J. Cortés
    A. Llombart-Cussac
    Clinical and Translational Oncology, 2020, 22 : 420 - 428
  • [39] Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer
    Chan, Arlene
    Shannon, Catherine
    de Boer, Richard
    Baron-Hay, Sally
    Redfern, Andrew
    Bauwens, Astrid
    Craft, Paul
    Webb, Suzanne
    Townsend, Amanda
    Kotasek, Dusan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 368 - 375
  • [40] A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
    Xu, Binghe
    Ma, Fei
    Ouyang, Quchang
    Li, Wei
    Jiang, Zefei
    Tong, Zhongsheng
    Liu, Yunjiang
    Li, Huiping
    Yu, Shiying
    Feng, Jifeng
    Wang, Shusen
    Hu, Xichun
    Zhu, Xiaoyu
    Zou, Jianjun
    CANCER RESEARCH, 2018, 78 (04)
12345